Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June:...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets...
Sarepta Therapeutics: Q1 Earnings Snapshot
Net product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of ELEVIDYS net product revenue and $228.6 million of PMO net product revenues ...
Barchart Research What to Expect from SRPT Earnings SRPT Generated May 5, 2026 Current Price $21.79 EPS Estimate $$0.39 Consensus Rating Hold Average Move 10.74% Sarepta's Gene Therapy Deaths Still Casting...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday,...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensation Committee...
In early clinical results, Sarepta’s αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1 ...
In early clinical results, Sarepta’s αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1 ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast...